Longeveron Inc. - Class A Common stock (LGVN)

Longeveron (NASDAQLGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced that it will present a late breaking poster at the 17th edition of the Clinical Trials on Alzheimer’s Disease Conference (“CTAD24”). The poster is titled “Lomecel-B inhibition of MMP14 activity predicts Lomecel-B bioactivity in the treatment of mild Alzheimer’s disease.” The conference is taking place in Madrid, Spain, from October 29, 2024, to November 1, 2024.

Longeveron (NASDAQLGVN), a clinical-stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, will be presenting at the 51st meeting of the Congenital Heart Surgeons’ Society. The meeting is scheduled for Oct. 27–28, 2024, in Chicago. Longeveron’s presentation will be part of the event’s Scientific Session II. Titled “Long-Term Transplant-Free Survival Is Improved in Hypoplastic Left Heart Syndrome with Cell-Based Therapy,” the presentation is slated to begin at 3:10 p.m. ET on Oct. 27.

Longeveron (NASDAQLGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, will be represented at the upcoming UBS Virtual Organ Restoration and Cell Therapy Day. According to the announcement, Longeveron CEO Wa’el Hashad will be participating in a fireside chat during the Oct. 15, 2024, virtual event. During the fireside chat, Hashad will be talking with Ash Verma, SMID-cap biotech and specialty pharma analyst for UBS Equity Research Ash Verma. The event is slated to begin at 3 p.m. ET.

Longeveron (NASDAQLGVN) is a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions. The company today announced that it will attend the Cell & Gene Meeting on the Mesa, organized by the Alliance for Regenerative Medicine . The conference is scheduled for October 7-9, 2024, in Phoenix, Arizona.

Longeveron (NASDAQLGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced a positive Type C meeting with the U.S. Food and Drug Administration (“FDA”). The meeting supported the advancement of Lomecel-B(TM) , a proprietary, scalable, allogeneic, investigational cellular therapy currently being evaluated in a Phase 2b clinical trial (“ELPIS II”) for hypoplastic left heart syndrome (“HLHS”) . According to the announcement, Longeveron and the FDA reached foundational alignment on ELPIS II primary and secondary endpoints as well as on the need to submit the company’s prespecified Statistical Analysis Plan (“SAP”) and Chemistry, Manufacturing and Controls (“CMC”) readiness plan, including Lomecel-B(TM) stability and comparability data, for prior review.

Longeveron (NASDAQLGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, will be spotlighted at next month’s H.C. Wainwright 26th Annual Global Investment Conference; the event is scheduled for Sept. 9–11, 2024. According to the announcement, company officials are slated to present on Sept. 10 at 5 p.m. ET. Following the conference, an archived replay of the webcast will be available on the Longeveron website.

Longeveron (NASDAQLGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is reporting on its second-quarter 2024 financial results, as well as key business milestones. Highlights of the report include positive data from LGNV’s phase 2a clinical trial designed to evaluate Lomecel-B(TM) in Alzheimer’s disease being presented at the Alzheimer’s Association International Conference(R) (“AAIC”); receiving both Regenerative Medicine Advanced Therapy (“RMAT”) designation and Fast Track designation for Lomecel-B from the U.S. Food and Drug Administration (“FDA”); reaching 70% enrollment in phase 2b clinical trial evaluating Lomecel-B in rare pediatric disease Hypoplastic Left Heart Syndrome (“HLHS”); and financing transaction and warrant exercises raising $15.3 million in gross proceeds, which will be used to fund continued clinical development.

Longeveron (NASDAQLGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is planning to release its second-quarter 2024 financial report after markets close on Aug. 14, 2024. The company also announced that it has scheduled a conference call and webcast on the same day to discuss the report and provide a company update; the call will begin at 4:30 p.m. ET. To access the call, dial 1.877-407-0789 and then use the conference ID 13747923. An archived replay of the webcast will be available on company website following the event.

Longeveron (NASDAQLGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is presenting results from its Clear Mind phase 2a clinical trial at the Alzheimer’s Association International Conference(R) (“AAIC”). The conference began on July 28, 2024, and runs through Aug. 1, 2024; the event is being held in person in Philadelphia as well as online. According to the announcement, a Featured Research Session oral presentation discussed findings that show Longeveron’s Lomecel-B improved cognitive function, quality of life and brain volume in the treatment of mild Alzheimer’s disease. The company also noted that the study met key objectives, including advancing data supporting favorable benefit/risk profile, supporting target engagement and providing additional support for the efficacy profile of Lomecel-B. In addition, Lomecel-B minimized the loss in brain volume in areas associated with Alzheimer’s disease. “As a medicinal signaling cell therapy that has multiple potential mechanisms of action to address inflammatory responses in the brain, Lomecel-B offers potential to address the underlying pathology of Alzheimer’s disease without the limitations of previous therapies,” said Longeveron CEO Wa’el Hashad in the press release. “We are very encouraged by the safety profile and efficacy evidence that support the differentiated therapeutic potential of Lomecel-B and lay the foundation for its future clinical development. We’re pleased to connect with the Alzheimer’s community at AAIC 2024 and contribute to the growing body of evidence that fuels the continued development of novel therapeutics for this devastating disease.”

Longeveron (NASDAQLGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, has closed on its previously announced registered direct offering. The offering, which was priced at-the-market following NASDAQ rules, included the issue and sale of 2,236,026 shares of LGVN Class A common stock (or common stock equivalents in lieu thereof). The shares were offered at a purchase price of $4.025 per share. The company also closed on a concurrent private placement involving the issue of unregistered warrants to purchase up to 2,236,026 shares of Class A common stock. The unregistered warrants have an exercise price of $3.90 per share and are immediately exercisable for 24 months following the date of issue. The company received an estimated $9 million in gross proceeds from the offering, before the deduction of fees and expenses. Longeveron anticipates using the funds for ongoing clinical and regulatory development of Lomecel-B(TM) as well as capital expenditures, working capital and other general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Longeveron Inc. (NASDAQLGVN) announced in July 2024 that the FDA granted Fast Track designation for its cellular therapy, Lomecel-B™, aimed at treating mild Alzheimer's Disease, accelerating its clinical development. The therapy also received RMAT designation, and the company announced a $9 million registered direct offering managed by H.C. Wainwright & Co.

Bravo Multinational (OTC: BRVO), a company dedicated to creating new revenue streams for brands of all types and sizes, is entering the telecommunications sector through its newly established, wholly owned subsidiary, Mobile 13 Inc. According to the announcement, Bravo is working to execute a business plan to become a key player in the telecom industry with the ability to generate revenue by supporting other mobile virtual network operators (“MVNOs”). The announcement noted that an MVNO provides cellular connectivity services by leasing network infrastructure from major mobile network operators (“MNOs”). Through Mobile 13, Bravo plans to become a mobile virtual network enabler (“MVNE”), offering a comprehensive platform for other MVNOs to quickly and efficiently launch their services. Mobile 13 is an MVNO designed to provide mobile phone services to consumers in 50 states and Puerto Rico; the entity specializes in the development of tailored mobile services for small to large employer groups, celebrities and national charities. “We are thrilled to introduce Mobile 13 as our new MVNO venture,” said Bravo Multinational COO Kayla Slick in the press release. “This strategic move aligns with Bravo’s current initiatives of providing turnkey technology and management services, allowing us to potentially expand revenue opportunities and product offerings by creating our own niche brands and partnering with both up-and-coming and well-established brands through white-label licensing agreements. . . . This trend underscores Bravo’s commitment to enhancing the customer experience while leveraging each new subscriber as a potential multiproduct consumer. Bravo’s mission is to bring together cost-effective and high-quality services for consumers, add new revenue streams for our partners and deliver value to our shareholders.”

Longeveron (NASDAQLGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, has entered into definitive agreements for the issue and sale of shares of Class A common stock. According to the announcement, the registered direct offering is comprised of up to 2,236,026 shares of LGVN Class A common stock (or common stock equivalents in lieu thereof) issued at a purchase price of $4.025 per share. The company also announced a concurrent private placement that includes issuing and selling of unregistered warrants for to an aggregate of 2,236,026 shares of Class A common stock. The exercise price of the unregistered warrants will be $3.90 per share; the warrants will be immediately exercisable for up to 24 months following the date of issuance. The company anticipates gross proceeds from the offering, which is expected to close on or about July 19, 2024, to reach an estimated $9 million before the deduction of fees and expenses. Longeveron plans to use the funds for ongoing clinical and regulatory development of Lomecel-B(TM) as well as capital expenditures, working capital and other general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Longeveron (NASDAQLGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to Lomecel-B(TM) for the treatment of mild Alzheimer’s Disease . Lomecel-B(TM) is a proprietary, scalable, allogeneic, investigational cellular therapy being evaluated across multiple indications. The Fast Track designation process aims to facilitate the development and expedite the review of new therapies intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. According to the announcement, the Fast Track designation granted to the Lomecel-B(TM) Alzheimer’s Disease program is the fifth special regulatory designation received for Lomecel-B(TM). “Fast Track designation is another important milestone for Longeveron and Lomecel-B(TM), which, along with the recent granting of Regenerative Medicine Advanced Therapy (“RMAT”) designation, recognizes the critical need for quickly advance novel, safe and effective investigational treatments for Alzheimer’s Disease, which has a devastating impact on patients and their families,” said, Wa’el Hashad , CEO of Longeveron.

Longeveron (NASDAQLGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for certain life-threatening and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (“FDA”) granted Regenerative Medicine Advanced Therapy (“RMAT”) designation to Lomecel-B(TM) for the treatment of mild Alzheimer’s disease. To the company’s knowledge based on publicly available information, Lomecel-B, a proprietary, scalable, allogeneic cellular investigational therapy being evaluated across multiple indications, is the first cellular therapeutic candidate to receive RMAT designation for Alzheimer’s. “The RMAT designation is an important milestone for Longeveron and the Lomecel-B program that recognizes the potential of our cellular therapy to have a positive impact on patients afflicted with this devastating disease,” said Joshua Hare, co-founder, chief science officer and chairman of the board at Longeveron. “Alzheimer’s disease is a neurodegenerative disorder that leads to progressive memory loss and death and currently has very limited therapeutic options. In the CLEAR MIND Phase 2a clinical trial, Lomecel-B demonstrated an overall slowing/prevention of disease worsening compared to placebo. The trial achieved the primary safety and secondary efficacy endpoints and showed statistically significant improvements in pre-specified clinical and biomarker endpoints in specific Lomecel-B groups compared to placebo.”

Longeveron (NASDAQLGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (“HLHS”) and Alzheimer’s disease, is announcing an addition to its board of directors. According to the announcement, senior healthcare investment banker Neha Motwani was elected to the board during the company’s recent Annual Meeting of Stockholders. Motwani brings more than two decades of experience to her new role as board member. Most recently she was managing director of healthcare investment banking at William Blair; she has also held a variety of roles at Truist Securities, Oppenheimer and Company, Stifel Financial, and Cowen and Company. “I am delighted to welcome Neha, with her tremendous healthcare industry experience, to the board of directors,” said Longeveron cofounder, chief science officer and board chair Joshua Hare in the press release. “Her extensive knowledge of biopharma company operations, financing and capital markets will bring significant value to Longeveron as we continue to advance Lomecel-B(TM), our proprietary, scalable, allogeneic cellular therapy. With five positive clinical trials across three indications, we believe Lomecel-B has the potential to be an important therapy for some of the most difficult diseases and conditions associated with aging.”

Longeveron (NASDAQLGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, has appointed Roger Hajjar, MD, director of the Gene and Cell Therapy Institute at Mass General Brigham, to its board of directors. An internationally recognized scientist, Dr. Hajjar’s cardiac gene therapy discoveries have spurred clinical trials for heart failure, and his methodologies for cardiac-directed gene transfer are currently utilized by investigators around the world. “I am delighted to welcome Roger, and his tremendous experience as a scientist, academic and operational executive, to the board of directors,” said Joshua Hare, co-founder, chief science officer and chairman of the board at Longeveron. “His thought leadership in gene and cell therapy will bring significant value to Longeveron as we continue to advance Lomecel-B(TM), our proprietary, scalable, allogeneic cellular therapy being evaluated in multiple indications. I look forward to collaborating with him to advance these important therapeutic development programs.”

Longeveron (NASDAQLGVN) is a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions. Longeveron presented at the Virtual Life Sciences Investor Forum on June 20. The company’s presentation is now available for online viewing 24/7 for 90 days.

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Longeveron (NASDAQLGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced its entry into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in April 2024. The resale of the shares of Class A common stock issuable upon exercise of the existing warrants is registered per an effective registration statement on Form S-1 (File No. 333-278995). The gross proceeds to Longeveron are expected to be approximately $4.4 million, prior to deducting placement agent fees and estimated offering expenses payable by the company. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

EQNX::TICKER_START (NYSEATNM),NASDAQ:BPTHNASDAQBPTH)(NASDAQ:LGVNNASDAQLGVN,(NASDAQ:SLSNASDAQ),(NYSE:BMYBMY) EQNX::TICKER_END

Longeveron (NASDAQLGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is participating in this week’s Emerging Growth Virtual Conference. The agenda for the event indicates Longeveron CEO and director Mohamed Wa’el Hashad will be speaking tomorrow at 1:45 p.m. ET; the two-day conference is slated for June 12–13. In addition, Longeveron has successfully completed an investigator meeting for ELPIS II, the ongoing phase 2b clinical trial that is designed to evaluate LGVN’s Lomecel-B(TM) as a potential adjunct treatment for hypoplastic left heart syndrome (“HLHS”). According to the announcement, the meeting included principal investigators and site staff from premiere infant and children’s treatment institutions across the country and included discussion regarding progress to date and operational implementation of the clinical trial. Multiple nationally recognized children’s treatment centers are participating in the ELPIS II study. HLHS is a rare pediatric congenital heart birth defect; with current HLHS treatment, only 50–60% of infants survive to adolescence. “We believe the data generated to date in HLHS support potential for Lomecel-B as a regenerative medical therapy to help these infants,” said Longeveron chief medical officer Nataliya Agafonova, MD, in the press release. “In the ELPIS I phase 1 clinical trial, participating infants experienced 100% transplant-free survival up to five years of age after receiving Lomecel-B compared to approximate 20% mortality rate observed from historical control data. ELPIS II is designed to further our understanding of Lomecel-B’s safety and efficacy in this patient population. With the collaboration of our outstanding investigative sites, we remain on track to complete enrollment of the clinical trial by the end of this year.”

PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at USD 1.83 billion in 2024, and is expected to reach USD 2.97 billion by 2029, growing at a CAGR of 10.15% during the forecast period (2024-2029). The report said: “Key factors propelling the growth of this market are the high incidence and prevalence of acute myeloid leukemia, advancements in pharmacology and molecular biology to promote drug development and increasing investments in research and development by pharmaceutical companies. According to the American Cancer Society, it is estimated that there will be 60,650 new leukemia cancer cases, of which 24,000 are expected to die in 2022 in the US. In addition, according to the same source, 20,050 new cases of acute myeloid leukemia (AML) are estimated in 2022 in the US. It will lead to increased adoption of AML therapies. The rising prevalence of AML in developed countries such as the US is expected to drive this market's growth. Furthermore, with the rising investment in research and development, there is an increasing number of clinical trials conducted to demonstrate the effectiveness of the drugs. It is expected to drive the market over the forecast period.” Active biotech and pharma companies in the markets this week include Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), Bio-Path Holdings, Inc., (NASDAQBPTH), Longeveron NASDAQ: LGVNNASDAQLGVN)(NASDAQ: SLSNASDAQSLS, Bristol Myers Squibb (NYSE: BMYNYSE).

Longeveron (NASDAQLGVN), a clinical-stage biotechnology company developing regenerative medicines, will be presenting at the Emerging Growth Virtual Conference this week. The two-day event is scheduled for June 12–13, 2024. Longeveron’s presentation is slated to begin at 1:45 p.m. ET on Wednesday, June 12. According to the announcement, anyone interested can view the presentation on the company’s website at that time. In addition, an archived version of the presentation will be available on the company website following the conference; the presentation will be available for approximately six months.